Personalised medicine in rectal cancer : understanding and predicting response to neoadjuvant chemoradiotherapy
Around 12-15% of patients with locally advanced rectal cancer (LARC) undergo a pathologically complete response (Tumour Regression Grade 4 - TRG4) to neoadjuvant chemoradiotherapy; the remainder exhibit a spectrum of tumour regression (TRG1-3). Understanding therapy-related genomic alterations may h...
| Main Author: | |
|---|---|
| Published: |
Queen's University Belfast
2017
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.725327 |